MacroGenics (MGNX) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

MacroGenics (MGNX) overview

MacroGenics (MGNX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 150m and operating profit of USD -72.8m; the year-end share price was 1.61 USD and market capitalisation was USD 102m. MacroGenics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get MacroGenics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 55.6mFY 2025
Share price1.61 USDFY 2025 year end
RevenueUSD 150mFY 2025
Operating profitUSD -72.8mFY 2025
Net earningsUSD -74.6mFY 2025
Market capitalisationUSD 102mFY 2025 year end

About MacroGenics

MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. Its product candidates include antibody-drug conjugates and multispecific antibodies, developed using its antibody technology platforms. The company also collaborates with biopharmaceutical partners on product development and operates a commercial-scale antibody manufacturing facility, providing contract development and manufacturing services for clinical and commercial products.

Generate the MacroGenics report

MacroGenics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for MacroGenics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on MacroGenics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.